4875 Stock Chart & Stats
¥230.00
¥1.00(0.47%)
At close: 4:00 PM EDT
¥230.00
¥1.00(0.47%)
Day’s Range― - ―
52-Week Range¥174.00 - ¥314.00
Previous CloseN/A
Volume6.40K
Average Volume (3M)39.26K
Market Cap
¥11.23B
Enterprise Value¥38.79M
Total Cash (Recent Filing)¥25.42M
Total Debt (Recent Filing)¥117.04K
Price to Earnings (P/E)―
Beta0.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding49,221,245
10 Day Avg. Volume72,410
30 Day Avg. Volume39,263
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.55
Price to Sales (P/S)156.89
P/FCF Ratio-6.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,280.61Price Target Upside456.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-40.93
Revenue Forecast (FY)¥46.55M
4875 FAQ
What was Medicinova’s price range in the past 12 months?
Medicinova lowest stock price was ¥174.00 and its highest was ¥314.00 in the past 12 months.
What is Medicinova’s market cap?
Medicinova’s market cap is ¥11.23B.
When is Medicinova’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicinova’s earnings last quarter?
Medicinova released its earnings results on Apr 26, 2023. The company reported -¥9.809 earnings per share for the quarter, beating the consensus estimate of -¥11.444 by ¥1.635.
Is Medicinova overvalued?
According to Wall Street analysts Medicinova’s price is currently Undervalued.
Does Medicinova pay dividends?
Medicinova does not currently pay dividends.
What is Medicinova’s EPS estimate?
Medicinova’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicinova have?
Medicinova has 49,221,245 shares outstanding.
What happened to Medicinova’s price movement after its last earnings report?
Medicinova reported an EPS of -¥9.809 in its last earnings report, beating expectations of -¥11.444. Following the earnings report the stock price went down -1.342%.
Which hedge fund is a major shareholder of Medicinova?
Currently, no hedge funds are holding shares in JP:4875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medicinova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
¥1,280.61 (456.79% Upside)
¥1,280.61 (456.79% Upside)
Blogger Sentiment
Neutral
JP:4875 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medicinova
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
4875 Stock 12 Month Forecast
Average Price Target
¥1,280.61
▲(456.79% Upside)
Technical Analysis
Precision BioSciences
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―










